This report represents a review of 1,641 routine autopsies. Prostate carcinoma was identified in 172 cases (10% of all autopsies) and was the direct or contributing cause of death in 29 (2%). Frequency of prostate carcinoma increased with increasing age, but the mortality rate was inversely related to age as indicated by 30% mortality in those younger than 60 years old, 24% of those between 60 and 70 years old, and 7.5% of those older than 70 years. Of those with carcinoma, 83% died of other, unrelated causes; of those who died, 80% had poorly differentiated (grade 3 or 4) tumors. Given the indolent biologic nature of well differentiated tumors in those older than 70 years, prostate carcinoma should not in most instances be regarded as life-threatening with or without treatment in older individuals. The tumor seems to be biologically more aggressive in younger men, especially those younger than 60 years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00007611-199007000-00016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.
J Zhejiang Univ Sci B
January 2025
Department of Orthopedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis.
View Article and Find Full Text PDFHemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT).
Case Rep Oncol Med
January 2025
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
In the past decade, the use of immune checkpoint therapy (ICT) has increased across many malignancies, including metastatic renal cell carcinoma as an option for frontline and subsequent lines of therapy. Despite the many therapeutic benefits of ICT, its use is complicated by the potential risk of immune-related adverse events (irAEs). One rare but potentially life-threatening irAE is hemophagocytic lymphohistiocytosis (HLH).
View Article and Find Full Text PDFCancer metastasis to the upper gastrointestinal tract-a case series.
J Gastrointest Oncol
December 2024
Medical Oncology Department, The Canberra Hospital, Canberra, ACT, Australia.
Background: Metastasis of non-gastrointestinal (non-GI) cancers to the upper GI tract is a rare occurrence, with limited cases reported in the literature. Recognising this type of metastasis is crucial, as it presents unique diagnostic and therapeutic challenges. This case series adds to the literature by discussing seven rare cases of non-GI cancer metastasising to the upper GI tract, emphasising the complications and clinical manifestations.
View Article and Find Full Text PDFFeasibility and safety of Taipei Veterans General Hospital Heavy Ion Therapy Center: The first carbon-ion irradiation facility in Taiwan.
J Chin Med Assoc
January 2025
Department of Heavy Particles and Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Background: Unlike conventional photon radiotherapy, particle therapy has the advantage of dose distribution. Carbon-ion radiotherapy is also advantageous in terms of biological effectiveness and other radiobiological aspects. These benefits lead to a higher response probability for previously known radioresistant tumor types.
View Article and Find Full Text PDFPrognostic values of molecular subtypes and SWI/SNF protein expression in de-differentiated/undifferentiated endometrial carcinoma.
Histopathology
January 2025
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Aims: Classification and risk stratification of endometrial carcinoma (EC) has transitioned from histopathological features to molecular classification, e.g. the ProMisE classifier, identifying four prognostic subtypes: POLE mutant (POLEmut) with almost no recurrence or disease-specific death events, mismatch repair deficient (MMRd) and no specific molecular profile (NSMP), with intermediate outcome and p53 abnormal (p53abn) with poor outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!